Shaun Grady, Vice President of Strategic Partnering &amp, Business Development at AstraZeneca ... being launched and commercialised globally. Forxiga is now approved in Europe, and there ...

AstraZeneca is investing in the broadest and ... For example, by building on the success of Forxiga (dapagliflozin), the first SGLT2 inhibitor to demonstrate a mortality benefit in chronic kidney ...

and means that Boehringer and Lilly can now compete head to head across all three indications with AstraZeneca's Forxiga (dapagliflozin). AZ's drug was approved for CKD in the EU and US in 2021 ...

AstraZeneca has cancelled plans for a £450m vaccine manufacturing plant in Liverpool, blaming a cut in funding from government. The investment, announced last year in the Tories' spring budget ...

In substance and timing, AstraZeneca's decision to cancel a planned expansion of its flu vaccine facility at Speke is a blow to the government's recent zeal for growth. Instead of injecting £450m ...

A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to address concerns over its business in China than on its earnings report alone.

AstraZeneca has abandoned a £450m investment in a major UK vaccine plant just days after Rachel Reeves vowed to “kick-start economic growth”. The drugmaker, which is Britain’s most valuable ...

LONDON, Jan 31 (Reuters) - AstraZeneca (AZN.L), opens new tab on Friday scrapped plans to invest 450 million pounds ($558.3 million) in its vaccine manufacturing plant in northern England ...

An AstraZeneca and Daiichi Sankyo drug designed to replace chemotherapy was cleared by US regulators for broader use in late-stage breast cancer patients. The Food and Drug Administration ...

Select listed pharmaceuticals companies including Pfizer Ltd, Novartis India Ltd, AstraZeneca Pharma India Ltd and GSK Pharmaceuticals Ltd shall be the beneficiaries of the budget announcements ...

Confirming the reversal on Friday, a spokesperson for AstraZeneca said: "Following discussions with the current Government, we are no longer pursuing our planned investment in Speke. "Several factors ...